RecruitingPhase 3NCT07286266

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer

Sponsor

GlaxoSmithKline

Enrollment

450 participants

Start Date

Jun 18, 2026

Study Type

INTERVENTIONAL

Conditions

Ovarian Neoplasms

Summary

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bevacizumab, a drug called Gemcitabine, and others for people with ovarian neoplasms. The study is currently recruiting participants at 5 locations. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMocertatug rezetecan

Mocertatug rezetecan will be administered

DRUGPaclitaxel

Paclitaxel will be administered

DRUGPegylated liposomal doxorubicin (PLD)

PLD will be administered

DRUGTopotecan

Topotecan will be administered

DRUGGemcitabine

Gemcitabine will be administered

DRUGPembrolizumab

Pembrolizumab will be administered

DRUGBevacizumab

Bevacizumab will be administered

Locations(5)

GSK Investigational Site

Randwick, New South Wales, Australia

GSK Investigational Site

Montreal, Quebec, Canada

GSK Investigational Site

Montreal, Quebec, Canada

GSK Investigational Site

Hyōgo, Japan

GSK Investigational Site

Osaka, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07286266

Related Trials

Centralization and Oncologic Outcomes in Ovarian Cancer

NCT070759397 locations

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804266 locations

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558125 locations

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

NCT0721379130 locations

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT04389632158 locations